Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01TWG
|
|||
| Drug Name |
Rozanolixizumab
|
|||
| Indication | Generalized myasthenia gravis [ICD-11: 8C60] | Approved | [1] | |
| Myasthenia gravis [ICD-11: 8C6Y; ICD-10: G70.0; ICD-9: 358] | Phase 2 | [2] | ||
| Company |
UCB Smyrna, GA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoglobulin Fc receptor (FCR) | Target Info | Antagonist | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761286 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.